Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei

Antimicrob Agents Chemother. 2019 Jan 29;63(2):e01739-18. doi: 10.1128/AAC.01739-18. Print 2019 Feb.

Abstract

Amphotericin B deoxycholate (DAmB) is a first-line agent for the initial treatment of talaromycosis. However, little is known about the population pharmacokinetics and pharmacodynamics of DAmB for talaromycosis. Pharmacokinetic data were obtained from 78 patients; among them, 55 patients had serial fungal CFU counts in blood also available for analysis. A population pharmacokinetic-pharmacodynamic model was fitted to the data. The relationships between the area under the concentration-time curve (AUC)/MIC and the time to blood culture sterilization and the time to death were investigated. There was only modest pharmacokinetic variability in the average AUC, with a mean ± standard deviation of 11.51 ± 3.39 mg·h/liter. The maximal rate of drug-induced kill was 0.133 log10 CFU/ml/h, and the plasma concentration of the DAmB that induced the half-maximal rate of kill was 0.02 mg/liter. Fifty percent of patients sterilized their bloodstreams by 83.16 h (range, 13 to 264 h). A higher initial fungal burden was associated with a longer time to sterilization (hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.36 to 0.70; P < 0.001). There was a weak relationship between AUC/MIC and the time to sterilization, although this did not reach statistical significance (HR, 1.03; 95% CI, 1.00 to 1.06, P = 0.091). Furthermore, there was no relationship between the AUC/MIC and time to death (HR, 0.97; 95% CI, 0.88 to 1.08; P = 0.607) or early fungicidal activity {slope = log[(0.500 - 0.003·(AUC/MIC)]; P = 0.319} adjusted for the initial fungal burden. The population pharmacokinetics of DAmB are surprisingly consistent. The time to sterilization of the bloodstream may be a useful pharmacodynamic endpoint for future studies. (This study has been registered at the ISRCTN registry under no. ISRCTN59144167.).

Keywords: PK-PD; Penicillium; Talaromyces; amphotericin; antifungal; pharmacodynamics; population pharmacokinetics; talaromycosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amphotericin B / pharmacokinetics
  • Amphotericin B / therapeutic use
  • Antifungal Agents / pharmacokinetics
  • Antifungal Agents / therapeutic use*
  • Area Under Curve
  • Deoxycholic Acid / pharmacokinetics
  • Deoxycholic Acid / therapeutic use
  • Drug Combinations
  • Female
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Penicillium / drug effects
  • Penicillium / pathogenicity
  • Talaromyces / drug effects
  • Talaromyces / pathogenicity*

Substances

  • Antifungal Agents
  • Drug Combinations
  • Deoxycholic Acid
  • Amphotericin B
  • amphotericin B, deoxycholate drug combination

Associated data

  • ISRCTN/ISRCTN59144167